Cargando…

Comparative efficacy and safety of oral P2Y(12) inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis

BACKGROUND: Currently, potent P2Y(12) inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines recommend the use of prasugrel over ticagrelor in patients with non-ST-elevation ACS...

Descripción completa

Detalles Bibliográficos
Autores principales: Farmakis, Ioannis T, Zafeiropoulos, Stefanos, Doundoulakis, Ioannis, Pagiantza, Areti, Karagiannidis, Efstratios, Moysidis, Dimitrios V, Stalikas, Nikolaos, Kassimis, George, Michalis, Lampros K, Karvounis, Haralambos, Giannakoulas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014125/
https://www.ncbi.nlm.nih.gov/pubmed/35428703
http://dx.doi.org/10.1136/openhrt-2021-001937

Ejemplares similares